Fortive Q4: EPS Tops, Revenue Misses, CEO Confident In 2025 Recovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 07 2025
0mins
Source: Benzinga
Fourth Quarter Results: Fortive Corporation reported a 2% year-over-year revenue growth to $1.620 billion, which fell short of expectations, while adjusted EPS of $1.17 exceeded consensus estimates. The company saw strong performance in its Intelligent Operating Solutions and Advanced Healthcare Solutions segments.
Future Outlook: For FY25, Fortive anticipates revenue between $6.23 billion and $6.35 billion, lower than the consensus estimate, with expected first-quarter revenue also below projections. The stock is currently down 3.57% in premarket trading.
Analyst Views on FTV
Wall Street analysts forecast FTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTV is 56.73 USD with a low forecast of 51.00 USD and a high forecast of 66.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
2 Buy
8 Hold
1 Sell
Hold
Current: 54.440
Low
51.00
Averages
56.73
High
66.00
Current: 54.440
Low
51.00
Averages
56.73
High
66.00
About FTV
Fortive Corporation is a technology solutions company. The Company's businesses design, develop, manufacture, and market products, software, and services, building on brand names, technologies, and market positions. The Company's segments include Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS). The Company's IOS segment provides advanced instrumentation, software and services to various customers enabling their mission-critical workflows. These offerings include electrical test and measurement, facility and asset lifecycle software applications, connected worker safety and compliance solutions across a range of vertical end markets. Its AHS segment supplies critical workflow solutions enabling healthcare providers to deliver patient care more efficiently. Its offerings include instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring and end-to-end clinical productivity software and solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
